{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:23:19Z","timestamp":1790166199931,"version":"4.1.0"},"reference-count":53,"publisher":"Impact Journals, LLC","issue":"31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,10,13]]},"DOI":"10.18632\/oncotarget.5890","type":"journal-article","created":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T03:25:47Z","timestamp":1443669947000},"page":"30487-30499","source":"Crossref","is-referenced-by-count":39,"title":["Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells"],"prefix":"10.18632","volume":"6","author":[{"given":"Bing Z.","family":"Carter","sequence":"first","affiliation":[{"name":"Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po Yee","family":"Mak","sequence":"additional","affiliation":[{"name":"Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan H.","family":"Mak","sequence":"additional","affiliation":[{"name":"Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian R.","family":"Ruvolo","sequence":"additional","affiliation":[{"name":"Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Schober","sequence":"additional","affiliation":[{"name":"Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"McQueen","sequence":"additional","affiliation":[{"name":"Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[{"name":"Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,9,29]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Stone","year":"2002","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction","volume":"107","author":"Holyoake","year":"2006","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Druker","year":"2011","journal-title":"J Clin Invest"},{"key":"4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Holyoake","year":"2002","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hon.813","article-title":"Therapeutic targets in chronic myeloid leukaemia","volume":"25","author":"Holyoake","year":"2007","journal-title":"Hematol Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","article-title":"Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli","volume":"19","author":"Bhatia","year":"2005","journal-title":"Leukemia"},{"key":"7","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2004-08-3373","article-title":"Punish the parent not the progeny","volume":"105","author":"Holyoake","year":"2005","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Eaves","year":"1999","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"White","year":"2013","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Weissman","year":"2004","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc2368","article-title":"Getting to the stem of chronic myeloid leukaemia","volume":"8","author":"Talpaz","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Geron","year":"2013","journal-title":"Cell Stem Cell"},{"key":"13","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/1535-7163.MCT-09-0386","article-title":"Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells","volume":"8","author":"Carter","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2011.285","article-title":"Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors","volume":"26","author":"Carter","year":"2012","journal-title":"Leukemia"},{"key":"15","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2011-06-361261","article-title":"Targeting of GSK3beta promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells","volume":"119","author":"Coluccia","year":"2012","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"Bhatia","year":"2013","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Bhatia","year":"2010","journal-title":"Cancer Cell"},{"key":"18","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Moriggl","year":"2005","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer activator of transcription 5-dependent expression of Bcl-xL","volume":"191","author":"Fernandez-Luna","year":"2000","journal-title":"J Exp Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","article-title":"ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms","volume":"140","author":"Strasser","year":"2008","journal-title":"Br J Haematol"},{"key":"21","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/sj.cdd.4402168","article-title":"Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia","volume":"14","author":"Taniwaki","year":"2007","journal-title":"Cell Death Differ"},{"key":"22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0092-8674(95)90412-3","article-title":"Tumor suppressor p53 is a direct transcriptional activator of the human bax gene","volume":"80","author":"Reed","year":"1995","journal-title":"Cell"},{"key":"23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Levine","year":"2000","journal-title":"Nature"},{"key":"24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1535-6108(03)00249-6","article-title":"No PUMA, no death: implications for p53-dependent apoptosis","volume":"4","author":"Zhang","year":"2003","journal-title":"Cancer Cell"},{"key":"25","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbabio.2008.10.005","article-title":"The mitochondrial p53 pathway","volume":"1787","author":"Moll","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"26","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/nature07986","article-title":"Cytoplasmic functions of the tumour suppressor p53","volume":"458","author":"Kroemer","year":"2009","journal-title":"Nature"},{"key":"27","first-page":"1001","article-title":"The MDM2-p53 interaction","volume":"1","author":"Petrenkol","year":"2003","journal-title":"Mol Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood-2005-02-0553","article-title":"MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy","volume":"106","author":"Andreeff","year":"2005","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood-2008-01-128611","article-title":"Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia","volume":"112","author":"Andreeff","year":"2008","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/blood-2005-12-5148","article-title":"Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia","volume":"108","author":"Andreeff","year":"2006","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1182\/blood-2005-08-3273","article-title":"MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells","volume":"107","author":"Gil","year":"2006","journal-title":"Blood"},{"key":"32","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/leu.2008.11","article-title":"MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2","volume":"22","author":"Zhou","year":"2008","journal-title":"Leukemia"},{"key":"33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/10428190009059278","article-title":"Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia","volume":"38","author":"Rak","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"34","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1073\/pnas.1213021110","article-title":"ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia","volume":"110","author":"Morris","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"35","first-page":"7635","article-title":"Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells","volume":"61","author":"Aulitzky","year":"2001","journal-title":"Cancer Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Bhatia","year":"2012","journal-title":"Cancer Cell"},{"key":"37","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s10495-010-0457-0","article-title":"Enhancement of imatinib-induced apoptosis of BCR\/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway","volume":"15","author":"Miura","year":"2010","journal-title":"Apoptosis"},{"key":"38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2011.7","article-title":"p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells","volume":"25","author":"Talpaz","year":"2011","journal-title":"Leukemia"},{"key":"39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.drup.2009.06.001","article-title":"Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches","volume":"12","author":"Andreeff","year":"2009","journal-title":"Drug ResistUpdat"},{"key":"40","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.4161\/cc.5.23.3520","article-title":"Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML","volume":"5","author":"Andreeff","year":"2006","journal-title":"Cell Cycle"},{"key":"41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2584","article-title":"p53 polymorphisms: cancer implications","volume":"9","author":"Hollstein","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"42","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Ye","year":"2011","journal-title":"J Exp Med"},{"key":"43","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.leukres.2013.04.018","article-title":"XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells","volume":"37","author":"Davis","year":"2013","journal-title":"Leuk Res"},{"key":"44","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1182\/blood-2011-02-334136","article-title":"p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1alpha-mediated down-regulation of CXCL12","volume":"118","author":"Andreeff","year":"2011","journal-title":"Blood"},{"key":"45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","article-title":"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells","volume":"7","author":"Konopleva","year":"2008","journal-title":"Mol Ca Ther"},{"key":"46","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/leu.2011.291","article-title":"Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn\/CXCR4 interactions in lipid rafts","volume":"26","author":"Konopleva","year":"2012","journal-title":"Leukemia"},{"key":"47","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-13-0410","article-title":"Combination of Imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CMLand","volume":"13","author":"Nagler","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Ruvolo","year":"2006","journal-title":"Cancer Cell"},{"key":"49","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Korsmeyer","year":"2005","journal-title":"Nature"},{"key":"50","first-page":"3603","article-title":"Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors","volume":"62","author":"Andreeff","year":"2002","journal-title":"Cancer Res"},{"key":"51","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"99","author":"Bhatia","year":"2002","journal-title":"Blood"},{"key":"52","first-page":"3937","article-title":"Functional evaluation of p53 and PTEN gene mutations in gliomas","volume":"6","author":"Ishioka","year":"2000","journal-title":"Clin Cancer Res"},{"key":"53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T13:56:07Z","timestamp":1718114167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,29]]},"references-count":53,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2015,10,13]]}},"alternative-id":["5890","26431162"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5890","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,29]]}}}